Biodexa Pharmaceuticals (BDRX) Assets Average (2014 - 2025)

Biodexa Pharmaceuticals has disclosed Assets Average across 12 years of filings, most recently posting $22.0 million for Q4 2025.

• In Q4 2025, Assets Average rose 20.1% year-over-year to $22.0 million; the TTM figure through Dec 2025 stood at $22.0 million (up 20.1% YoY), while the FY2025 annual figure was $21.4 million, up 33.92% from the prior year.
• Assets Average came in at $22.0 million for Q4 2025 at Biodexa Pharmaceuticals, up from $19.4 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $22.0 million in Q4 2025 to a low of $8.2 million in Q2 2023.
• Average Assets Average over 5 years is $15.2 million, with a median of $15.1 million recorded in 2024.
• Year-over-year, Assets Average plunged 55.09% in 2021 and surged 86.79% in 2024.
• Over 5 years, Assets Average stood at $12.3 million in 2021, then climbed by 20.67% to $14.8 million in 2022, then fell by 22.14% to $11.5 million in 2023, then surged by 58.81% to $18.3 million in 2024, then increased by 20.1% to $22.0 million in 2025.
• Per Business Quant data, the three most recent Assets Average figures were $22.0 million in Q4 2025, $19.4 million in Q2 2025, and $18.3 million in Q4 2024.